Medpace Holdings (MEDP) stock plummeted 7.21% to trade at $XXX on Tuesday amid the broader market sell-off. The healthcare company's shares were hit hard during the intraday trading session.
The decline came after Truist Financial analyst Jailendra Singh maintained a Hold rating on Medpace Holdings. While the analyst provided no specific price target, the reiterated Hold stance likely contributed to investor concerns over the company's near-term outlook.
Despite the sell-off, some analysts remain optimistic about Medpace's prospects in the healthcare sector. In separate notes, analysts highlighted Medpace as one of their top healthcare picks alongside companies like Incyte.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。